Efforts to develop antiviral agents must carefully consider strategies to overcome deficiencies in molecular screening.
Core C of the Midwest AViDD Center centralizes medicinal chemistry, drug metabolism and pharmacokinetics, and computational hit-to-lead support functions. As a result, Core C will be agile and responsive to opportunities and emerging discoveries.
We will adjust support, favoring projects showing the highest potential for success. There is a mixture of low-, moderate-, and higher-risk targets among the five projects, including approaches that might identify broad-spectrum agents. The assembled experts in Core C are appropriately focused on issues of drug-likeness and maximizing the potential for orally bioavailable drug development candidates in multiple target areas for viruses with high pandemic potential.